These emerging therapies , Semaglutide , represent a remarkable advancement in addressing metabolic dysfunction and conceivably other conditions . They are classified as GLP-1 receptor agonists , meaning they function to mimic the endogenous GLP-1 peptide, enhancing insulin secretion and reducing